Drugs & Targets Hopkins and BMS announce five-year collaboration to study resistance to checkpoint blockers and develop combination immunotherapies. November 11, 2016Vol.42 No.42
Drugs & Targets Amgen and Janssen Biotech to evaluate combination of Amgen’s Kyprolis and Janssen’s Darzalex in multiple clinical studies in multiple myeloma November 11, 2016Vol.42 No.42
Drugs & Targets FDA Approves BMS’s Opdivo for Head and Neck Cancer Indication November 11, 2016Vol.42 No.42
Drugs & Targets VENTANA ALK (D5F3) CDx gets FDA approval to use on the VENTANA BenchMark ULTRA automated slide stainer November 11, 2016Vol.42 No.42
Drugs & Targets LEE011, Novartis’s selective cyclin dependent kinase inhibitor, granted FDA Priority Review November 11, 2016Vol.42 No.42
Drugs & Targets Roche Receives FDA Approval for Tecentriq Complementary Diagnostic in NSCLC November 04, 2016Vol.42 No.41
Drugs & Targets Hoffmann-LaRoche’s Alecensaro receives Health Canada approval NSCLC November 04, 2016Vol.42 No.41
Drugs & Targets BMS receives Health Canada conditional approval for Opdivo-Yervoy combination November 04, 2016Vol.42 No.41
